Hejing Biotech announced that the SGC001 injection independently developed by its holding subsidiary Shunjing Pharmaceutical is carrying out phase IIa clinical studies on the “Expected Severe Acute Pancreatitis” indication; the study began one after another at various research centers in August 2026, and recently completed the first case of patient enrollment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.